← vTv Therapeutics Inc. (VTVT) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
vTv Therapeutics Inc. (VTVT)
Pharmaceutical Preparations · market cap $22M · as of 2026-10-27
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-04-15 (est.)
Phase 3
Pipeline
7
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
vTv Therapeutics (VTVT) is a 23-employee clinical-stage pharmaceutical company whose lead asset is cadisegliatin, in Phase 3 for Type 1 diabetes. Our data also lists six Phase 2 programs in Type 2 diabetes, Type 1 diabetes, obesity and venous thromboembolism. The next major catalyst on our calendar is an estimated Phase 3 cadisegliatin event on 2027-04-15 (importance 9/10), preceded by estimated earnings on 2026-11-05.
The catalyst path
- 2027-04-15 (est.)Phase 3 · Cadisegliatinimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| TTP054 | Phase 2 | Type 2 Diabetes Mellitus |
| Cadisegliatin | Phase 3 | Diabetes Mellitus, Type 1 |
| GK1-399 (formerly TTP399) | Phase 2 | Type 2 Diabetes Mellitus |
| TTP889 | Phase 2 | Venous Thromboembolism |
| TTP399 | Phase 2 | Diabetes Mellitus, Type 1 |
| TTP273 | Phase 2 | Type 2 Diabetes Mellitus |
| TTP435 | Phase 2 | Obesity |
Price & technical context
3-month
-30.6%
6-month
-24.1%
12-month
+2.7%
52-wk range
$23.50–$42.72
vs 50-day MA
-19.1%
vs 200-day MA
-27.9%
Realized vol
71.7%
Max drawdown
-44.9%
Daily closes through 2026-11-04. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for VTVT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.